Evaxion Biotech A/S (NASDAQ:EVAX) vs. Renovaro (NASDAQ:RENB) Financial Comparison

Renovaro (NASDAQ:RENB) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Risk and Volatility

Renovaro has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.26, meaning that its share price is 126% less volatile than the S&P 500.

Valuation and Earnings

This table compares Renovaro and Evaxion Biotech A/S”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Renovaro	N/A	N/A	-$39.68 million	($0.78)	-0.53
Evaxion Biotech A/S	$278,000.00	55.08	-$22.12 million	($4.33)	-0.65

Evaxion Biotech A/S has higher revenue and earnings than Renovaro. Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.4% of Renovaro shares are owned by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Renovaro and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Renovaro	N/A	-67.10%	-51.71%
Evaxion Biotech A/S	N/A	N/A	-108.14%

Analyst Ratings

This is a summary of current ratings and target prices for Renovaro and Evaxion Biotech A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Renovaro	0	0	0	0	N/A
Evaxion Biotech A/S	0	0	2	0	3.00

Evaxion Biotech A/S has a consensus price target of $11.00, suggesting a potential upside of 288.69%. Given Evaxion Biotech A/S’s higher possible upside, analysts plainly believe Evaxion Biotech A/S is more favorable than Renovaro.

Summary

Evaxion Biotech A/S beats Renovaro on 6 of the 11 factors compared between the two stocks.

About Renovaro

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.